MedImmune and Micromet AG, a wholly owned subsidiary of Micromet, Inc., will receive a milestone payment from MedImmune triggered by the IND filing. Micromet’s Proprietary BiTE® Platform has Potential to Improve Treatment in Multiple Tumor Types. All-Cash Transaction Values Micromet at. The initial development plan contemplates EUR 25 million in funding of Micromet R&D activities if two BiTE antibodies are advanced to IND.
|Published (Last):||23 April 2004|
|PDF File Size:||16.41 Mb|
|ePub File Size:||19.61 Mb|
|Price:||Free* [*Free Regsitration Required]|
For the second BiTE program, Micromet is eligible to receive an additional cash payment upon initiation of the program, milestones, royalties, and development funding comparable to the first program.
Micromet Announces Solid Tumor BiTE Antibody Collaboration with Amgen | FierceBiotech
Micromer is being developed in collaboration with Serono. Alder received an LL. Two Phase 2 clinical trials for the treatment of patients with breast cancer and prostate cancer have been completed in Q3,with adecatumumab MTa recombinant human monoclonal antibody. This site uses Akismet to reduce spam. Expands Management and Appoints Christopher P. We note that the most promising candidate at Micromet is blinatumomab MTalso being co-developed with MedImmune, micdomet the treatment of acute lymphoblastic leukemia ALLa type of blood cancer.
Amgen Pays $10M Up Front in Cancer Deal with Micromet
The air conditioning system in the new Tesla Model X has three modes: National Entrepreneurship Awards Top 25 Biotech Companies of Vodafone Business Services Digilogue – Your guide micromft digitally transforming your business. New York, Aug 30 IANS In a finding that could make the process of removing salt from seawater easier, faster and cheaper than ever before, researchers have discovered that carbon micromer of a certain size act as the perfect filter for salt — the most abundant water contaminant.
Micromet has established collaborations with MedImmune, Inc. Prior to that, Mr. MT is an antibody generated with the proprietary bispecific Mkcromet engager BiTE antibody platform.
Micromet: Latest News & Videos, Photos about Micromet | The Economic Times
Government 4 Jul, Learn how your comment data is processed. Micromet and Amgen entered a deal under which Micromet will work to discover antibodies against three undisclosed tumor targets from Amgen. They have been directed to keep nebulizers and other related equipment in good condition and to be ready to meet with any exigency, the ministry stated in a release.
This is the second highest pollution level of this year. Top 10 Molecular Millionaires of All News Videos Photos. Micromet will be primarily responsible for the discovery and preclinical development of the BiTE antibodies.
Now you can 3D print glass 23 Apr, In addition to the finance, business development and legal functions, Micromet is planning to expand the US headquarters by adding a development team for US clinical trials and regulatory interactions with the FDA.
Bio-weapon experts aren’t buying the Tesla Model X’s bio-weapon defense mode 1 Oct, Under the terms of the deal, MedImmune is responsible for the development and commercialization inr the candidate in the US and outside Europe. Dental treatments burning a hole in your pocket?
Delhi’s air quality turns ‘severe’: CSR Compendium Touching lives of many.
EPFO may give your money more stock play next year Updated: The War on Food. Moreover, the heavy dependence on blinatumomab is also a concern — any hiccup in its clinical development programs will weigh heavily on the stock.
Good News for Micromet
Following the acceptance of the application by the FDA, MT is expected to move into human studies in the first half of Dec 31, In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations.